Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2011 October;102(5) > Minerva Medica 2011 October;102(5):373-9

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878


eTOC

 

REVIEWS  


Minerva Medica 2011 October;102(5):373-9

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine

Vizzardi E., Bonadei I., D’Aloia A., Del Magro F., Piovanelli B., Bontempi L., Curnis A., Dei Cas L.

Section of Cardiovascular diseases, Department of Experimental and Applied Medicine, University of Study of Brescia, Brescia, Italy


PDF  


Heart rate is a major determinant of cardiac output, myocardial oxygen consumption and coronary blood flow under physiological and pathological conditions. Experimental and clinical data have demonstrated that heart rate reduction is the main mechanism for reducing ischemia, improving left ventricular function, decreasing the risk of plaque rupture and post myocardial infarction mortality. Nowadays betablockers are the best class of drugs that can lower heart rate in patients with cardiovascular diseases, but sometimes their use is limited by some contraindications. Ivabradine is a new drug that reduces the firing rate of pacemaker cells in the sinoatrial node through a different mechanism with respect to betablockers. The purpose of this review is to investigate the main trials that support Ivabradine adoption in clinical practice.

top of page

Publication History

Cite this article as

Corresponding author e-mail

enrico.vizzardi@tin.it